Dr. Olsen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12697 E 51st St
Tulsa, OK 74146Phone+1 918-505-3200Fax+1 918-505-3253
Summary
- Mark Olsen, MD, is an Oncology specialist based in Tulsa, OK. He completed his medical education, Internal Medicine residency, and Medical Oncology fellowship at the University of Wisconsin School of Medicine & Public Health and its affiliated hospitals and clinics between 1992 and 1998. Dr. Olsen has a notable number of published works in reputable journals, such as Cancer and Clinical Genitourinary Cancer, where his studies on advanced renal cell carcinoma have been widely cited. He has also participated in clinical trials focused on cancer-related acute pain. His professional accolades include the CMS Meaningful Use Stage 1 Certification from OncoEMR, Altos Solutions, Inc in 2012-2013.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1995 - 1998- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1992 - 1995
University of Wisconsin School of Medicine & Public HealthClass of 1992
Certifications & Licensure
OK State Medical License 1998 - 2025
WI State Medical License 1996 - 1999
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- Acute Pain Caused by Paclitaxel in Patients With Cancer Start of enrollment: 2009 Feb 01
Publications & Presentations
PubMed
- 27 citationsSafety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor John Percent
Cancer. 2021-11-16 - 19 citationsSafety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.Joshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, Todd M Bauer, Ana Molina
Clinical Genitourinary Cancer. 2020-12-01 - 47 citationsSafety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.Nicholas J Vogelzang, Mark R Olsen, Joshua J McFarlane, Edward Arrowsmith, Todd M Bauer
Clinical Genitourinary Cancer. 2020-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
